GUIDELINES FOR THE USE OF FRESH FROZEN PLASMA

Abstract Recommendations, which aim at standardising and rationalising clinical indications for the transfusion of fresh frozen plasma (FFP) in Belgium, were drawn up by a working group of the Superior Health Council. For this purpose the Superior Health Council organised an expert meeting devoted to “Transfusion Guidelines: Pathogen reduction, products and indications for the transfusion of plasma” in collaboration with the Belgian Haematological Society. The experts discussed the indications for the transfusion of FFP, pathogen reduction for FFP and the practical issues of administering FFP and plasma-derived concentrates. The recommendations formulated by the experts were validated by the working group with the purpose of harmonising FFP transfusion in Belgian hospitals.

[1]  B. Solheim.  Pathogen reduction of blood components. , 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[2]  C. Wade,et al.  The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. , 2007, The Journal of trauma.

[3]  H. Cohen,et al.  Serious hazards of transfusion: a decade of hemovigilance in the UK. , 2006, Transfusion medicine reviews.

[4]  J. George,et al.  A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura , 2006, Transfusion.

[5]  J. Seghatchian,et al.  The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. , 2006, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[6]  B. Healy,et al.  Effect of fresh‐frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities , 2006, Transfusion.

[7]  J. Seghatchian,et al.  Update on pathogen reduction technology for therapeutic plasma: an overview. , 2006, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[8]  J. Castilla,et al.  Presymptomatic Detection of Prions in Blood , 2006, Science.

[9]  Lorne L Holland,et al.  Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. , 2006, American journal of clinical pathology.

[10]  Lorne L Holland,et al.  Toward Rational Fresh Frozen Plasma Transfusion , 2006 .

[11]  W. Murphy,et al.  Beyond leukodepletion: removing infectious prions by filtration , 2005, Transfusion.

[12]  J. Segal,et al.  Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence‐based review , 2005, Transfusion.

[13]  J. Castilla,et al.  Detection of prions in blood , 2005, Nature Medicine.

[14]  I. López-Vílchez,et al.  Effects of a new pathogen‐reduction technology (Mirasol PRT) on functional aspects of platelet concentrates , 2005, Transfusion.

[15]  P. Leblond,et al.  Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet , 2005, British journal of haematology.

[16]  P. Hellstern.  Solvent/detergent-treated plasma: composition, efficacy, and safety. , 2004, Current opinion in hematology.

[17]  S. Brunskill,et al.  Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials , 2004, British journal of haematology.

[18]  R. Goodrich,et al.  Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light , 2004, Transfusion.

[19]  J. Cid,et al.  Methylene blue‐photoinactivated plasma vs. fresh‐frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura , 2004, Vox sanguinis.

[20]  G. Findlay,et al.  Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients , 2004, British journal of haematology.

[21]  C. Prowse,et al.  Methylene blue‐treated fresh‐frozen plasma: what is its contribution to blood safety? , 2003, Transfusion.

[22]  P. Hellstern,et al.  Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. , 2002, Thrombosis research.

[23]  E. Seifried,et al.  Practical guidelines for the clinical use of plasma. , 2002, Thrombosis research.

[24]  J. de la Rubia,et al.  Role of methylene blue‐treated or fresh‐frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura , 2001, British journal of haematology.

[25]  R. Sabatowski,et al.  Failure of Autologous Fresh Frozen Plasma to Reduce Blood Loss and Transfusion Requirements in Coronary Artery Bypass Surgery , 2001, Anesthesiology.

[26]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[27]  J. Neuberger,et al.  A randomized trial of solvent/detergent‐treated and standard fresh‐frozen plasma in the coagulopathy of liver disease and liver transplantation , 1999, Transfusion.

[28]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[29]  F. Rosendaal,et al.  Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.

[30]  D. Sutton,et al.  Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura , 1996, British journal of haematology.

[31]  Northern Neonatal Nursing Initiative Trial Group.  Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years , 1996, The Lancet.

[32]  A. Giovanetti,et al.  Use of blood products for elective surgery in 43 European hospitals , 1994, Transfusion medicine.

[33]  P E Pepe,et al.  Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. , 1994, The New England journal of medicine.

[34]  A. Prince,et al.  Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. , 1992, Blood.

[35]  J. Moake,et al.  Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura , 1990, American journal of hematology.

[36]  L. Schonberger,et al.  Transfusion transmission of human prion diseases. , 2008, Transfusion medicine reviews.

[37]  J. George,et al.  Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP) , 2001, Journal of clinical apheresis.

[38]  J. Sweeney,et al.  Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura , 1995, Journal of clinical apheresis.